Background: The majority of people with epilepsy (PWE) live in low- and middle-income countries (LMICs). However, they remain largely untreated and the bulk of resources are used to treat patients in the developed world. This disparity constitutes a challenge for neuroepidemiological studies on a global scale. In the past, several studies have focused on diverse populations in disparate countries at various periods of time and for particular purposes. The specificity of different contexts and circumstances makes it difficult to analyse PWE as a group either qualitatively or quantitatively. Such methodological limitations are further complicated by a lack of logistical support. There is a lack of interest in conducting studies, which results in inadequate funding and, in addition, there is the considerable challenge of publishing research reports from LMICs in peer-reviewed international journals. Methods: This paper focuses on methodological problems related to studies in LMICs and attempts to give the reasons for their limitations using epilepsy as an example. Results: Regional conditions and environmental factors must be given careful consideration in the research design because of the importance of understanding the challenges of living in these environments. There are further limitations to the successful implementation of studies. Existing information on epilepsy is often not readily accessible; there is a lack of census data, and migratory patterns into cities make enumeration and sampling even more challenging. As there is usually no well-developed healthcare system a door-to-door screening process is often the only way to identify those with convulsive epilepsy. The questionnaire and study design should preferably be adapted from standardized protocols, and pre-tested and validated in local conditions. Conclusions: Systematic reviews and meta-analyses of studies in LMICs can provide data on the burden, risk factors, treatment and outcome of epilepsy only if the primary studies used are properly conducted using uniform and comparable methodology. The use of consistent replicable neuroepidemiological methods in primary studies and systematic reviews enable reduction of the treatment gap and better epilepsy care.

1.
WHO: Atlas: epilepsy care in the world 2005. Geneva, World Health Organization, 2005.
2.
Meinardi H, Scott RA, Reis R, et al: The treatment gap in epilepsy: the current situation and ways forward. Epilepsia 2001;42:136-149.
3.
Greenhalgh T: How to read a paper: papers that summarise other papers (systematic reviews and meta-analyses). BMJ 1997;315:672.
4.
Ngugi AK, Kariuki SM, Bottomley C, et al: Incidence of epilepsy: a systematic review and meta-analysis. Neurology 2011:77:1005-1012.
5.
Ngugi AK, Bottomley C, Kleinschmidt I, et al: Estimation of the burden of active and life-time epilepsy: a meta-analytic approach. Epilepsia 2010;51:883-890.
6.
Mbuba CK, Ngugi AK, Newton CR, et al: The epilepsy treatment gap in developing countries: a systematic review of the magnitude, causes, and intervention strategies. Epilepsia 2008;49:1491-1503.
7.
Meyer AC, Dua T, Ma J, et al: Global disparities in the epilepsy treatment gap: a systematic review. Bull World Health Organ 2010:88:260-266.
8.
Eysenck H: Problems with meta-analysis; in Chalmers I, Altman DG (eds): Systematic Reviews. London, BMJ, 1995.
9.
Thompson SG: Why sources of heterogeneity in meta-analysis should be investigated; in Chalmers I, Altman DG (eds): Systematic Reviews. London, BMJ, 1995.
10.
Ngugi AK, Bottomley C, Kleinschmidt I, et al: Prevalence of active convulsive epilepsy in Sub-Saharan Africa and associated risk factors: cross-sectional and case-control studies. Lancet Neurol 2013;12:253-263.
11.
Crepin S, Houinato D, Nawana B, et al: Link between epilepsy and malnutrition in a rural area of Benin. Epilepsia 2007;48:1926-1933.
12.
Mbuba CK, Ngugi AK, Fegan G, et al: Risk factors associated with the epilepsy treatment gap in Kilifi, Kenya: a cross-sectional study. Lancet Neurol 2012;11:688-696.
13.
Quet F, Odermatt P, Preux PM: Challenges of epidemiological research on epilepsy in resource-poor countries. Neuroepidemiology 2008;30:3-5.
14.
Preux PM, Druet-Cabanac M: Epidemiology and aetiology of epilepsy in sub-Saharan Africa. Lancet Neurol 2005:4:21-31.
15.
Tran DS, Odermatt P, Le TO, et al: Prevalence of epilepsy in a rural district of central Lao PDR. Neuroepidemiology 2006;26:199-206.
16.
WHO Neurosciences Programme: Research protocol for measuring the prevalence of neurological disorders in developing countries. Geneva, World Health Organization, 1982.
17.
Schoenberg BS: Clinical neuroepidemiology in developing countries: neurology with few neurologists. Neuroepidemiology 1982;1:137-142.
18.
Li SC, Schoenberg BS, Wang CC, et al: Epidemiology of epilepsy in urban areas of the People's Republic of China. Epilepsia 1985:26:391-394.
19.
Osuntokun BO, Schoenberg BS, Nottidge VA, et al: Research protocol for measuring the prevalence of neurologic disorders in developing countries: results of a pilot study in Nigeria. Neuroepidemiology 1982;1:143-153.
20.
Bharucha NE, Bharucha EP, Dastur HS: Pilot survey of the prevalence of neurologic disorder in the Parsi community of Bombay. Am J Prev Med 1987;3:293-299.
21.
Preux PM, Chea K, Chamroeun H, et al: First-ever, door-to-door cross-sectional representative study in Prey Veng province (Cambodia). Epilepsia 2011:52:1382-1387.
22.
Houinato D, Preux PM, Charriere B, et al: Interest of LQAS method in a survey of HTLV-I infection in Benin (West Africa). J Clin Epidemiol 2002;55:192-196.
23.
Rafael F, Houinato D, Nubukpo P, et al: Sociocultural and psychological features of perceived stigma reported by people with epilepsy in Benin. Epilepsia 2010;51:1061-1068.
24.
Quet F, Preux PM, Huerta M, et al: Determining the burden of neurological disorders in populations living in tropical areas: who would be questioned? Lessons from a Mexican rural community. Neuroepidemiology 2011;36:194-203.
25.
Debrock C, Preux PM, Houinato D, et al: Estimation of the prevalence of epilepsy in the Benin region of Zinvie using the capture-recapture method. Int J Epidemiol 2000;29:330-335.
26.
Placencia M, Sander JWAS, Shorvon SD, et al: Validation of a screening questionnaire for the detection of epileptic seizures in epidemiological studies. Brain 1992;115:783-794.
27.
Preux PM: Questionnaire in a study of epilepsy in tropical countries (in French). Bull Soc Pathol Exot 2000;93:276-278.
28.
Diagana M, Preux PM, Tuilla M, et al: Screening for epilepsy in tropical areas: validation of a questionnaire in Mauritania (in French). Bull Soc Pathol Exot 2006;99:103-107.
29.
Déglise C, Suggs LS, Odermatt P: SMS for disease control in developing countries: a systematic review of mobile health applications. J Telemed Telecare 2012;18:273-281.
30.
King JD, Buolamwini J, Cromwell EA, Panfel A, Teferi T, Zerihun M, Melak B, Watson J, Tadesse Z, Vienneau D, Ngondi J, Utzinger J, Odermatt P, Emerson PM: A novel electronic data collection system for large-scale surveys of neglected tropical diseases. PLoS One 2013;8:e74570.
31.
Commission on Epidemiology and Prognosis, International League against Epilepsy: Guidelines for epidemiologic studies on epilepsy. Epilepsia 1993;34:592-596.
32.
Carpio A, Hauser WA: Epilepsy in the developing world. Curr Neurol Neurosci Rep 2009;9:319-326.
33.
Singh G, Singh P, Singh I, et al: Epidemiologic classification of seizures associated with neurocysticercosis: observations from a sample of seizure disorders in neurologic care in India. Acta Neurol Scand 2006;113:233-240.
34.
Carpio A, Hauser WA: Remote symptomatic epilepsies and epileptic syndromes: etiological spectrum; in Murthy JMK, Senanayake N (eds): Epilepsy in the Tropics. Austin, Landes Bioscience, 2006.
35.
Fisher RS, van Emde Boas W, Blume W, et al: Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia 2005;46:470-472.
36.
Berg AT, Berkovic SF, Brodie MJ, et al: Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia 2010;51:676-685.
37.
Thurman DJ, Beghi E, Begley CE, et al: Standards for epidemiologic studies and surveillance of epilepsy. Epilepsia 2011;52(suppl 7):2-26.
38.
Shorvon SD, Farmer PJ: Epilepsy in developing countries: a review of epidemiological, sociocultural, and treatment aspects. Epilepsia 1988;29(suppl 1):S36-S54.
39.
Paraiso MN, Houinato D, Guerchet M, et al: Validation of the use of historical events to estimate the age of subjects aged 65 years and over in Cotonou (Benin). Neuroepidemiology 2010:35:12-16.
40.
Burneo JG, Tellez-Zenteno J, Wiebe S: Understanding the burden of epilepsy in Latin America: a systematic review of its prevalence and incidence. Epilepsy Res 2005;66:63-74.
41.
Mac TL, Tran D-S, Quet F, et al: Epidemiology, aetiology, and clinical management of epilepsy in Asia: a systematic review. Lancet Neurol 2007;6:533-543.
42.
Bharucha NE, Shorvon SD: Epidemiology in developing countries; in Engel J Jr, Pedley TA (eds): Epilepsy: A Comprehensive Textbook. Philadelphia, Lippincott-Raven Publishers, 1997, pp 105-118.
43.
Diop AG, Hesdorffer DC, Logroscino G, Hauser WA: Epilepsy and mortality in Africa: a review of the literature. Epilepsia 2005;46(suppl 11):33-35.
44.
Heaney DC, Beagley CE: Economic evaluation of epilepsy treatment: a review of the literature. Epilepsia 2002;43(suppl 4):10-16.
45.
Birbeck G, Chomba E, Atadzhanov M, et al: The social and economic impact of epilepsy in Zambia: a cross-sectional study. Lancet Neurol 2007;6:39-44.
46.
Cooper SC, Lund C, Kakuma R: The measurement of poverty in psychiatric epidemiology in LMIC: critical review and recommendations. Soc Psychiatry Psychiatr Epidemiol 2012;47:1499-1516.
47.
Dumas M, Preux PM: Epilepsy in tropical areas (in French). Bull Acad Natl Med 2008;192:949-960.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.